6/2/2016 | PP | Oncothyreon arranges $50 million at-the-market sales agreement
|
2/18/2015 | PP | Oncothyreon greenshoe exercised for $22.05 million public stock sale
|
2/6/2015 | PP | Oncothyreon prices $2 million of series B convertible preferred shares
|
2/6/2015 | PP | Oncothyreon prices $20.25 million public offering of stock at $1.50
|
2/6/2015 | CV | New Issue: Oncothyreon prices $2 million of series B convertible preferred shares
|
2/5/2015 | CV | Market Commentary: New Microchip flat to higher in gray market, old bonds active; Twitter adds ahead of earnings
|
2/5/2015 | PP | Oncothyreon plans convertible preferred, common stock offerings
|
2/5/2015 | CV | Oncothyreon plans convertible preferred, common stock offerings
|
12/31/2014 | CV | Market Commentary: Outlook 2015: U.S. convertibles primary notches multi-year high; volume expected to climb
|
9/18/2014 | PP | Oncothyreon prices $20 million public offering of its stock at $2.00
|
9/18/2014 | CV | Market Commentary: PDL BioPharma drops after auditor news; Gilead remains weaker; secondary softness persists
|
9/18/2014 | PP | Oncothyreon terminates its $50 million at-the-market sales agreement
|
9/18/2014 | CV | Market Commentary: Morning Commentary: PDL BioPharma 4% convertibles drop; two small, new deals in the market
|
9/18/2014 | CV | New Issue: Oncothyreon prices $20 million of convertible preferred shares
|
9/17/2014 | CV | Oncothyreon plans public offers of convertible preferred, common shares
|
9/17/2014 | PP | Oncothyreon plans public offer of common, convertible preferred shares
|
9/17/2014 | PP | Oncothyreon announces plans to price public offering of common stock
|
5/30/2013 | PP | Oncothyreon arranges $10 million registered direct offering of units
|
4/3/2012 | PP | Oncothyreon concludes $54.05 million public offering of common stock
|
3/29/2012 | PP | Oncothyreon prices $47 million public sale of common stock at $4.00
|
3/28/2012 | PP | Oncothyreon to price public sale of common stock through Cowen and Co.
|
2/3/2012 | PP | Oncothyreon arranges $50 million at-the-market equity sales agreement
|
12/23/2011 | CVHYPF | Oncothyreon files $150 million shelf covering stock, preferreds, debt
|
5/4/2011 | PP | Oncothyreon seals $46 million public stock sale; greenshoe exercised
|
4/29/2011 | PP | Oncothyreon prices $40 million public sale of common stock at $4.00
|
4/1/2011 | CVHYPF | Oncothyreon files $75 million shelf covering stock, debt, preferreds
|
2/9/2011 | PP | Oncothyreon secures $12.5 million via loan, warrant agreement with GE
|
9/27/2010 | PP | Oncothyreon gives details on $14.85 million private placement of units
|
9/24/2010 | PP | Oncothyreon plans to sell units for $14.9 million in private placement
|
7/7/2010 | PP | New Issue: Oncothyreon publicizes plans for $20 million committed equity facility
|
7/7/2010 | PP | Market Commentary: AsherXino, iSOFT, Oncothyreon get equity lines; DS Smith closes £47.16 million stock placement
|
8/4/2009 | PP | New Issue: Oncothyreon announces $15 million registered direct offering of stock
|
5/20/2009 | PP | New Issue: Oncothyreon orchestrates $11.06 million registered direct offering of equity units
|
3/20/2008 | CV | Oncothyreon files $50 million shelf registration
|